Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Operating Income (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Operating Income for 6 consecutive years, with -$4.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Income fell 78.84% to -$4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$16.3 million, a 28.99% decrease, with the full-year FY2024 number at -$11.2 million, up 35.41% from a year prior.
  • Operating Income was -$4.7 million for Q3 2025 at Vivos Therapeutics, up from -$4.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $8.7 million in Q4 2021 to a low of -$7.0 million in Q2 2022.
  • A 5-year average of -$3.8 million and a median of -$4.3 million in 2023 define the central range for Operating Income.
  • Biggest YoY gain for Operating Income was 239.41% in 2021; the steepest drop was 202.83% in 2021.
  • Vivos Therapeutics' Operating Income stood at $8.7 million in 2021, then plummeted by 169.61% to -$6.1 million in 2022, then rose by 29.34% to -$4.3 million in 2023, then surged by 34.5% to -$2.8 million in 2024, then tumbled by 68.64% to -$4.7 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Operating Income are -$4.7 million (Q3 2025), -$4.9 million (Q2 2025), and -$3.9 million (Q1 2025).